Reliable quantitation of GLP‑1 analogues in bioanalysis and IP 2026 updates

Join us for an insightful webinar exploring reliable quantitation of GLP 1 analogues in bioanalysis and IP 2026 updates.

This session will cover the strategic approaches for robust quantitation of GLP 1 analogues, emphasizing control strategy and method robustness over sensitivity. It also covered challenges such as matrix effects and analyte instability, along with key updates on Indian Pharmacopoeia monograph development, harmonization, and global recognition. in short as per the guideline's

Speaker: Dr. Pankaj Partani (Head-Application Support at SCIEX, PhD in Pharmaceutical Sciences)

Key highlights

• Robust GLP 1 quantitation is not about pushing limits—it’s about making the right strategic choices at every step.
• Reliable GLP 1 data is built on control strategy, robustness, not just sensitivity.
• Challenges in GLP 1 quantitation arise from matrix effects, instability, and non specific losses, not instrument capability.

Dr. Gaurav Pratap Singh Jadaun, Ph.D. (Senior Principal Scientific Officer
Indian Pharmacopoeia Commission, Ghaziabad)

Key highlights

• The monograph development process
• Their revision and harmonization, updates of the general chapters, international recognition of the IP, and IP Online portal